Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Galapagos NV
Analysts are scratching their heads over what direction the Belgian biotech will take in the coming months and years, with all eyes on an R&D day in October.
During Q2, biopharma merger and acquisition value reached $25.4bn and drew in $27.3bn in potential deal value from alliances. Device company M&A values reached $2.7bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $534.3m.
RA drug development has been slow to revise the trial design paradigm despite agreement on the drawbacks of placebo controls and crossover elements, but FDA biostatistician Levin sees promise in non-inferiority designs.
The Belgian firm has the go-ahead from the US FDA for an advanced depression program for ANT-01 including the endpoint of improvement in cognitive function, which could differentiate its label.
- Drug Discovery Technologies
- Large Molecule
- Other Names / Subsidiaries
- Abound Bio, Inc.
- CellPoint B.V.
- Discovery Partners International
- Inpharmatica Ltd.
- Sareum Holdings plc.